November 2026 — The rare kidney disease (RKD) community celebrates a huge landmark milestone following the U.S. Food and Drug Administration’s (FDA) approval of GAZYVA® (obinutuzumab) as the first and only therapy for adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria.
This historic approval provides patients with a targeted, disease-modifying treatment option for a serious condition with high unmet needs. Proteinuria serves as a key indicator of kidney damage and a critical predictor of long-term kidney preservation, making the achievement of complete remission a vital goal to maintain kidney function and prevent serious complications.
Primary membranous nephropathy (pMN) is a rare, chronic autoimmune condition that causes potentially irreversible kidney damage. When left untreated, up to 30% of patients progress to kidney failure within 10 years. People living with pMN often experience fatigue, edema (swelling), and significant physical and emotional challenges, placing a substantial human and economic burden on patients, families, and healthcare systems alike.
Gazyva is a targeted therapy designed to address B cells, a critical underlying driver of the disease. By turning decades of specialized antibody engineering into tangible outcomes, Gazyva offers a more effective approach to achieve durable disease control compared to conventional options like tacrolimus.
The FDA approval is based on robust data from the Phase III MAJESTY study, which demonstrated:
- 36.1% of adults achieving complete remission (CR) of proteinuria at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% CI: 18.2 to 44.0; p<0.001).
- Superiority in overall remission rates (complete or partial remission) at week 104 (50% vs. 12.9%; adjusted difference 37.8%; p<0.001).
- Complete remission at week 76 (36.1% vs. 8.6%; adjusted difference 27.4%; p<0.001).
With today’s approval, there are now 13 FDA-approved treatment options for rare, protein-spilling kidney diseases, including therapies for IgAN, focal segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G), primary IC-MPGN, and nephrotic syndrome.
- EMPAVELI (pegcetacoplan) – Approved for C3G and primary IC-MPGN
- FABHALTA (iptacopan) – Approved for C3G and IgAN
- FILSPARI (esparsentán) - Approved for IgAN and FSGS
- GAZYVA (obinutuzumab) – Approved for nephrotic syndrome and primary membranous nephropathy
- TARPEYO (budesonide) – Approved for IgAN
- TRUTAKNA (atacicept) - Approved for IgAN
- ULTOMIRIS (ravulizumab) – Approved for IgAN
- VANRAFIA (atrasentan) – Approved for IgAN
- VOYXACT (sibeprenlimab) - Approved for IgAN